Cargando…

Cabozantinib‐nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

Nivolumab and cabozantinib are approved agents in mRCC patients after sunitinib/pazopanib (TKI) failure. However, the optimal sequence, cabozantinib then nivolumab (CN) or nivolumab then cabozantinib (NC), is still unknown. The CABIR study aimed to identify the optimal sequence between CN and NC aft...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vano, Yann‐Alexandre, Phan, Letuan, Gravis, Gwenaelle, Korakis, Iphigénie, Schlürmann, Friederike, Maillet, Denis, Bennamoun, Mostefa, Houede, Nadine, Topart, Delphine, Borchiellini, Delphine, Barthelemy, Philippe, Ratta, Raffaele, Ryckewaert, Thomas, Hasbini, Ali, Hans, Sophie, Emambux, Sheik, Cournier, Sandra, Braychenko, Elena, Elaidi, Réza‐Thierry, Oudard, Stéphane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Cancer Therapy and Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541795/ https://www.ncbi.nlm.nih.gov/pubmed/35603906 http://dx.doi.org/10.1002/ijc.34126

Ejemplares similares

Comparative Efficacy of First-Line Immune-Based Combination Therapies in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis
por: Elaidi, Reza, et al.
Publicado: (2020)

REchallenge of NIVOlumab (RENIVO) or Nivolumab-Ipilimumab in Metastatic Renal Cell Carcinoma: An Ambispective Multicenter Study
por: Vauchier, Charles, et al.
Publicado: (2022)

Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France
por: Houédé, Nadine, et al.
Publicado: (2015)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

Modeled Early Longitudinal PSA Kinetics Prognostic Value in Rising PSA Prostate Cancer Patients after Local Therapy Treated with ADT +/− Docetaxel
por: Carrot, Aurore, et al.
Publicado: (2022)

Optimal cut-off for neutrophil-to-lymphocyte ratio: Fact or Fantasy? A prospective cohort study in metastatic cancer patients
por: Vano, Yann-Alexandre, et al.
Publicado: (2018)

Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study
por: Guillaume, Zoé, et al.
Publicado: (2022)

Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma
por: Jebali, M., et al.
Publicado: (2017)

Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas
por: Lu, Xiaofan, et al.
Publicado: (2023)

A standardized methodical approach to characterize the influence of key parameters on the in vitro efficacy of extracorporeal photopheresis
por: Laulhé, Marie, et al.
Publicado: (2019)

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs
por: Beuselinck, B, et al.
Publicado: (2015)

Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments
por: Procureur, Adrien, et al.
Publicado: (2021)

Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies
por: Guillaume, Zoé, et al.
Publicado: (2022)

Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer †
por: Ferrero, Jean-Marc, et al.
Publicado: (2023)

Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
por: Simonaggio, Audrey, et al.
Publicado: (2021)

Resistance to cancer immunotherapy in metastatic renal cell carcinoma
por: Moreira, Marco, et al.
Publicado: (2020)

MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights
por: Simonaggio, Audrey, et al.
Publicado: (2022)

New Artificial Intelligence Score and Immune Infiltrates as Prognostic Factors in Colorectal Cancer With Brain Metastases
por: Randrian, Violaine, et al.
Publicado: (2021)

LC-MS based metabolomic profiling for renal cell carcinoma histologic subtypes
por: Jing, Lun, et al.
Publicado: (2019)

Testbeds and research infrastructure: 8th international ICST conference, TRIDENTCOM 2012, Thessanoliki, Greece, June 11-13, 2012, revised selected papers
por: Korakis, Thanasis, et al.
Publicado: (2012)

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors
por: Karaki, Soumaya, et al.
Publicado: (2016)

Cabozantinib in the treatment of advanced renal cell carcinoma: design, development, and potential place in the therapy
por: Grassi, Paolo, et al.
Publicado: (2016)

Wave dynamics alteration by discontinuous flexible mats of artificial seagrass can support seagrass restoration efforts
por: Villanueva, Raúl, et al.
Publicado: (2023)

Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases
por: Roussille, Pauline, et al.
Publicado: (2018)

Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients
por: Roubaud, Guilhem, et al.
Publicado: (2015)

To exploit the 5 ‘R’ of radiobiology and unleash the 3 ‘E’ of immunoediting: ‘RE’-inventing the radiotherapy-immunotherapy combination
por: Daguenet, Elisabeth, et al.
Publicado: (2020)

Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas
por: Thouvenin, Jonathan, et al.
Publicado: (2022)

Sorafenib for Older Patients With Renal Cell Carcinoma: Subset Analysis From a Randomized Trial
por: Eisen, Tim, et al.
Publicado: (2008)

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial
por: Bahl, A., et al.
Publicado: (2013)

Higher nodal yield with robot-assisted pelvic lymph node dissection for bladder cancer compared to laparoscopic dissection: implications for more accurate staging
por: Arora, Amandeep, et al.
Publicado: (2020)

Wandering along the epigenetic timeline
por: Topart, Clémence, et al.
Publicado: (2020)

Os et articulations /
por: Ryckewaert, Antoine, 1919-
Publicado: (1971)

The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
por: Nassif, Elise F., et al.
Publicado: (2021)

Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020)

Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
por: Vendrell, Julie A., et al.
Publicado: (2023)

First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma: What Are the Most Appropriate Combination Therapies?
por: Vano, Yann-Alexandre, et al.
Publicado: (2021)

Double Culprit Lesions in a Patient With ST-Segment Elevation Myocardial Infarction: Should I Stent or Should I Go?
por: Hage, Georges, et al.
Publicado: (2021)

Deciphering Brain Metastasis Stem Cell Properties From Colorectal Cancer Highlights Specific Stemness Signature and Shared Molecular Features
por: Desette, Amandine, et al.
Publicado: (2023)

Case Report: Successful Treatment of Steroid-Refractory Immune Checkpoint Inhibitor-Related Pure Red Cell Aplasia With Cyclosporin
por: Gérard, Alexandre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lsgklq5ko58sah30v1st090mld